Nov 13, 2021 / 05:00PM GMT
Operator
Good day, ladies and gentlemen, and welcome to EyePoint Pharmaceuticals Data Call at American Academy of Ophthalmology. (Operator Instructions)
I would now like to turn the conference over to your first speaker today, Mr. George Elston, CFO. Sir, the floor is yours.
George O. Elston - EyePoint Pharmaceuticals, Inc. - CFO & Head of Corporate Development
Thank you, and thank you all for joining us on today's conference call to discuss our positive top line safety and efficacy results from the Phase I DAVIO trial evaluating EYP-1901 for the treatment of Wet AMD.
I am George Elston, the CFO of EyePoint Pharmaceuticals, and with me today is Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Operating Officer; Dr. Dario Paggiarino, Chief Medical Officer; and Dr. Carl Regillo, KOL and Chairman of the company's Scientific Advisory Board.
Earlier this morning, we issued a press release detailing our results. We are using slides to accompany our remarks today, which will be found in the Investor Relations tab on the
EyePoint Pharmaceuticals Inc Phase 1 DAVIO Trial Of EYP-1901 Results Conference Call Transcript
Nov 13, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers